Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Q3 FY23 Earnings Presentation
21 slides from Jb Chemicals & Pharmaceuticals's earnings presentation, Feb 8, 2023
Slide 1: NSE filing cover letter
February 8, 2023 National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400051. Stock Symbol: JBCHEPHARM Dear Sir, Subject: Investor Presentation Enclosed please find the presentation the Company proposes to make to inves
Slide 2: JB Pharma – Q3 and 9M FY23 Investor Presentation
JB Pharma – Q3 and 9M FY23 Investor Presentation February 8, 2023 www.jbpharma.com jbpharma/ 1
Slide 3: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 4: Synergistic acquisitions
Synergistic acquisitions Dosage forms Gi leader %+ ROCE Oo State of the art facilities N Leadership detsiip OS hie 5 P fat A iO M ADOC j Jf J Dosage fOrmS State of the art facilities Cardiac leader Market-beating 24-26% Operating margin guidance GI leade Leadership Dosage forms 24-26% Operating marg
Slide 5: Corporate Snapshot
Corporate Snapshot Brands among top 300 brands Years of operations with 46 consistent track record across multiple businesses 6 (IQVIA MAT Dec’22 data), contributing over 60% of domestic formulations revenues Regulated/semi-regulated Global manufacturer of 40+ markets of presence through direct oper
Slide 6: Corporate Snapshot – Financial Overview
Corporate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) ^Op EBITDA Margin (%) 42% 27.4% 25.0% 24.5% 29% 21.3% 24% 22% # 18.6% 15.4% 15% 25% 2,424 2,387 2,043 19% 18% 1,643 1,775 1,413 13% 10% 272 449 386 322 139 194 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 9M FY23 ROE (%) ROCE
Slide 7: World Class Manufacturing Facilities
World Class Manufacturing Facilities • State of the Art manufacturing facilities 7 • Global Regulatory Accreditations 40+ • Dosage forms produced 10 6
Slide 8: Q3 and 9M FY23 Business Performance
Q3 and 9M FY23 Business Performance 7
Slide 9: CEO’s Message
CEO’s Message “JB continues its growth journey delivering strong financial performance in the quarter. Our organic business outpaced the market, whereas our inorganic portfolio added to the upsides with better than anticipated momentum. Our inorganic strategy is built around growing the India busine
Slide 10: Financial Overview: Q3 and 9M FY23
Financial Overview: Q3 and 9M FY23 Revenues (INR crores) 33% 2,387 o JB registered YoY revenue growth of 32% in Q3 FY23 and 33% in 9M FY23 1,800 32% o Domestic formulations business maintained its market 793 601 beating performance growing at 42% in Q3 FY23 and 39% in 9M FY23 • Excluding sales from
Slide 11: EBITDA Analysis
EBITDA Analysis INR crore Q3 FY23 Q3 FY22 9M FY23 9M FY22 Revenue 793 601 2387 1800 Reported EBITDA 175 128 532 419 Non Cash ESOP Charge 18 25 52 38 Included in Employee Benefits expense Operating EBITDA (excluding ESOP charge) 193 153 584 457 Operating EBITDA margins 24.3% 25.5% 24.5% 25.4% 10
Slide 12: Financial Overview Q3 and 9M FY23
Financial Overview Q3 and 9M FY23 Op. EBITDA* (INR crores) 25.4% o Operating EBIDTA* grew by 26% in Q3 FY23 and 28% in 9M FY23 25.5% 24.5% 584 • Operating EBIDTA* margin was at 24.3% in Q3 FY23 vs 25.5% in Q3 FY22 24.3% 457 28% o Gross margins was 62.3% in Q3 FY23 vs 65.7% in Q3 FY22 26% 193.0 • Hig
Slide 13: Domestic Business Q3 and 9M FY23
Domestic Business Q3 and 9M FY23 Domestic Formulations (INR crores) 1260 o Domestic business continued to record over INR 400 crore revenue 39% for the third quarter in a row 904 o Domestic business, excluding sales from acquired brands, grew at mid-teens, out-pacing industry growth o New Product co
Slide 14: Acquisition of the Razel (Rosuvastatin) franchise
Acquisition of the Razel (Rosuvastatin) franchise The acquisition marks JB Pharma’s entry into the ‘Statin’ market which is the largest segment in cardiac therapy Transaction Value: INR 314 crores excluding tax and working capital Rosuvastatin and its combinations registered 3-year sales CAGR of 14%
Slide 15: Razel to bring Synergy Benefits to JB Pharma
Razel to bring Synergy Benefits to JB Pharma Leverages the existing Go-To-Market model focussed for this segment and further strengthens our chronic portfolio With the acquisition of Razel, we are now present in the 3 most progressive cardiology segments • Statins : Razel • Anti Hypertension : Cilac
Slide 16: JB Pharma Breaks into the Top 10 Companies in Cardiology
JB Pharma Breaks into the Top 10 Companies in Cardiology Rank Company IQVIA MAT MAR'22 Ranks Company IQVIA MAT Dec'22 Grand Total 22282 Grand Total 22973 1 SUN 2308 1 SUN 2511 2 TORRENT PHARMA 1693 2 TORRENT PHARMA 1799 3 LUPIN LIMITED 1537 3 LUPIN LIMITED 1458 4 USV 1197 4 USV 1373 5 CIPLA 1171 5 C
Slide 17: Revenue Analysis: International Business Q3 and 9M FY23
Revenue Analysis: International Business Q3 and 9M FY23 23% 11% 386 315 241 267 92% o International business continues its strong performance with -4% revenue growing at 23% in Q3 FY23 and 26% in 9M FY23 96 50 24 23 • International formulations recorded highest ever quarterly sales Total Internation
Slide 18: Q3 and 9M FY23 Financial Performance (Consolidated)
Q3 and 9M FY23 Financial Performance (Consolidated) Particulars Q3 FY23 Q3 FY22 YoY Growth 9M FY23 9M FY22 YoY Growth Revenue from Operations 793 601 32% 2387 1800 33% Cost of Goods Sold 299 206 45% 893 630 42% Gross Profit 494 395 25% 1494 1170 28% Gross Profit Margins 62.3% 65.7% 62.6% 65.0% Emplo
Slide 19: JB Pharma – FY 2023 Objectives – On Track
JB Pharma – FY 2023 Objectives – On Track Domestic business should consistently outperform market growth Acquired Brands will continue to gain traction in this financial year International business should continue to deliver good sales growth Demand from International formulations especially
Slide 20: About JB Pharma
About JB Pharma J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | For further information, please ISIN: INE572A01028), established in 1976, is one contact: of the fastest growing pharmaceutical companies in India and a leading player in the hypertension Lakshay Kataria, Chief Financial Officer segment. B
Slide 21: Thank you
GOOD PEOPLE _for GOOD HEALTH Thank you 000 www.jbpharma.com
J.B. Chemicals & Pharmaceuticals — Q3 FY23 Earnings Presentation on 6ix